GET DAILY SIGNALSWhy Is Doximity (DOCS) Stock Down -5.61% Today?
Key Takeaways
- Shares of DOCS fell 5.61% to $31.32, down from a prior close of $33.18, in early trading Thursday.
- The decline followed fiscal Q2 results that beat estimates but showed sharp margin compression tied to heavy AI investment.
- Adjusted EBITDA fell 12% year over year, with the margin narrowing to 51% from 60% a year earlier.
- Net revenue retention softened to 103% from 107%, and an analyst downgrade added to selling pressure.
- Broader sentiment toward high-multiple healthcare-technology names added to the downside bias.
- Traders are watching whether AI-related products can reaccelerate revenue growth in the coming quarters.
- For more detail on valuation and technicals, explore Price Targets, Earnings, and Forecast pages.
- Discover which strategies are performing best right now with Trending AI Robots.
Opening Summary
Doximity, Inc. (DOCS), the San Francisco-based digital networking platform for U.S. medical professionals, saw its shares slide sharply on Thursday after the company reported fiscal second-quarter results that beat Wall Street's top- and bottom-line estimates but revealed meaningful erosion in profitability. The stock traded down 5.61% to $31.32, compared with the prior session's close of $33.18. The market reaction centered on margin compression driven by the company's escalating spending on artificial-intelligence products, which overshadowed better-than-expected revenue and a raised full-year outlook.
Earnings Beat Overshadowed by Margin Compression
The core driver of the decline was the composition of Doximity's quarterly results rather than the headline numbers. The company reported revenue of $174.5 million, up 4% year over year and ahead of the roughly $170.8 million consensus estimate, while adjusted earnings per share of $0.36 edged past the $0.35 Wall Street expected. Despite those beats, investors focused on profitability. Adjusted EBITDA fell 12% year over year to $88.9 million, and the adjusted EBITDA margin contracted to 51% from 60% a year earlier. Net income dropped to $34.7 million from $62.1 million, and GAAP diluted EPS declined to $0.18 from $0.31, reflecting higher cost of revenue, a jump in stock-based compensation, and a sharply higher tax provision.
AI Investment Cycle Weighs on the Bottom Line
Management framed the quarter as a deliberate investment period, with spending scaling rapidly to support growing clinician adoption of AI-driven tools. Cost of revenue rose more than 50%, and research-and-development and sales-and-marketing expenses each increased materially. While executives highlighted record engagement—quarterly active workflow prescribers grew 34% year over year—and a health-system AI client base that expanded to more than 190 institutions, the near-term cost of that growth pressured margins. The market reaction suggests investors are demanding clearer evidence that AI revenue can outpace the corresponding expense growth in future quarters.
Analyst Downgrade and Retention Concerns
Compounding the earnings-driven move, an analyst downgrade added to the selling pressure, as a firm cited concerns over decelerating growth metrics. Net revenue retention fell to 103% from 107% in the prior quarter, and retention among the top 20 customers slipped to 106% from 112%. The number of customers generating more than $500,000 in trailing revenue also declined. These softening retention figures raised questions about the durability of the company's growth trajectory, even as management pointed to early traction in AI Search, now described as an eight-figure bookings product with 16 of the top 20 pharmaceutical companies signed on.
Market Context and Trading Activity
The decline in DOCS occurred against a backdrop of cautious sentiment toward high-valuation healthcare-technology stocks, where investors have grown less tolerant of margin giveback in exchange for growth. Trading volume was elevated relative to recent sessions as investors repositioned following the earnings release. The move also pushed the stock through near-term support levels established during its recent advance, reinforcing technically driven selling. With the shares trading below several short-term moving averages, the price action reflected both fundamental disappointment and a technical breakdown following a period of strength.
What Comes Next for DOCS
Investor attention now shifts to whether Doximity's AI initiatives can convert record engagement into reaccelerating revenue growth. Management guided fiscal third-quarter revenue to between $195 million and $196 million and raised its full-year revenue outlook to a midpoint of $680.5 million, above consensus. Key catalysts ahead include the pharmaceutical upfront booking season and the pace of AI Search revenue recognition, which management expects to ramp gradually through calendar 2027. Risks include continued margin pressure from AI compute costs, uncertain retention trends, and execution risk tied to lengthy medical-legal review cycles for new products. The next earnings report will be closely watched for signs that the investment cycle is beginning to pay off.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to consider. Explore the page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
DOCS saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for DOCS moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 45 of the 56 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DOCS moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 20 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 77%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DOCS as a result. In 60 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for DOCS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DOCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
DOCS broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The 50-day moving average for DOCS moved above the 200-day moving average on October 14, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +3.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DOCS advanced for three days, in 210 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 124 of 179 cases where DOCS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. DOCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 51 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.326) is normal, around the industry mean (4.492). P/E Ratio (36.122) is within average values for comparable stocks, (13.458). Projected Growth (PEG Ratio) (0.590) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (7.776) is also within normal values, averaging (6.065).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DOCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement